ScinoPharm and Raffles collaborate on development and manufacture of celecoxib
ScinoPharm Taiwan and Chinese company Raffles PharmaTech are to collaborate on the manufacture of celecoxib, a non-steroidal and anti-inflammatory analgesic active pharmaceutical ingredient.
By combining the research and development knowledge of Raffles and the commercial production capability of ScinoPharm in Changshu, both sides are hoping to exploit business opportunities in the US market.
After the product launch, both parties will share the profits, and expect that products will be available in the USA by 2018. According to the forecast from Global Data, celecoxib sales in the USA are expected to reach $500 million in 2018.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Generics
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze